A Letter from our Directors

Welcome to SYNAPshot the Institute for Psychedelics and Neurotherapeutics Newsletter!

This fall has been a season of milestones for the IPN. 

Our research continues to push boundaries. The team recently developed a new LSD analog called JRT, designed to promote neuroplasticity while minimizing hallucinogenic potential. This innovation was published in the Proceedings of the National Academy of Science and reflects one of our central goals—creating compounds that capture the therapeutic potential of psychedelics while improving safety and accessibility for patients.

Collaboration across the IPN was also on full display when the team published an important mechanistic study in Nature Neuroscience about how tabernanthalog (TBG) promotes neuroplasticity.  In total, the collaboration involved 5 UC Davis labs, 4 academic labs from across the world, and 3 private companies!

We’re also excited to welcome Dr. Corey Webster, our new Project Scientist whose broad expertise in neuroscience coupled with his specific experience in aging/neurodegeneration research, will help us move the Institute in exciting new directions.

As always, thank you for believing in our mission and joining us on this extraordinary journey to find new solutions for promoting mental wellness.
 

Sincerely,

David E. Olson and John A. Gray